Study identifier:MI-CP198
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 2b, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous MEDI-528 in Adults with Uncontrolled Asthma
asthma
Phase 2
No
-
All
329
Interventional
18 Years - 65 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Jul 2014 by MedImmune, LLC
MedImmune, LLC
None
To study the effectiveness and safety of multiple-doses of MEDI-528 on asthma control in adult participants with uncontrolled, moderate-to-severe, persistent asthma.
The primary objective of this study is to evaluate the effect of multiple-dose subcutaneous (SC) administration of MEDI-528 on asthma control in adults with uncontrolled, moderate-to-severe, persistent asthma.
Location
Location
Omaha, NE, United States, 68131
Location
Kissimmee, FL, United States, 34741
Location
Sacramento, CA, United States, 95819
Location
Pell City, AL, United States, 35128
Location
Los Angeles, CA, United States, 90025
Location
San Antonio, TX, United States, 78229
Location
Mt. Laurel, NJ, United States, 08054
Location
Minneapolis, MN, United States, 55402
Arms | Assigned Interventions |
---|---|
Experimental: MEDI528 30 mg MEDI-528 at a dose of 30 mg administered as a subcutaneous injection every 2 weeks for 24 weeks | Biological/Vaccine: MEDI528 30 mg MEDI-528 at a dose of 30 mg administered as a subcutaneous injection every 2 weeks for 24 weeks |
Experimental: MEDI528 100 mg MEDI-528 at a dose of 100 mg administered as a subcutaneous injection every 2 weeks for 24 weeks | Biological/Vaccine: MEDI528 100 mg MEDI-528 at a dose of 100 mg administered as a subcutaneous injection every 2 weeks for 24 weeks |
Experimental: MEDI528 300 mg MEDI-528 at a dose of 300 mg administered as a subcutaneous injection every 2 weeks for 24 weeks | Biological/Vaccine: MEDI528 300 mg MEDI-528 at a dose of 300 mg administered as a subcutaneous injection every 2 weeks for 24 weeks |
Experimental: Placebo Placebo administered as a subcutaneous injection every 2 weeks for 24 weeks | Other: Placebo Placebo administered as a subcutaneous injection every 2 weeks for 24 weeks |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.